Volume 131, Issue 2 pp. 133-142
RESEARCH ARTICLE

Is Oncoplastic Surgery Safe in High-Risk Breast Cancer Phenotypes?

Gabriel De La Cruz Ku

Gabriel De La Cruz Ku

Department of Surgery, Universidad Cientifica del Sur, Lima, Peru

Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts, USA

Search for more papers by this author
Carly Wareham

Carly Wareham

Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Search for more papers by this author
Caroline King

Caroline King

Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Search for more papers by this author
Akash Koul

Akash Koul

Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Search for more papers by this author
Anshumi Desai

Anshumi Desai

Department of Surgery, University of Miami Medical School, Miami, Florida, USA

Search for more papers by this author
Sarah M. Persing

Sarah M. Persing

Division of Plastic and Reconstructive Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Division of Surgical Oncology, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Search for more papers by this author
Salvatore Nardello

Salvatore Nardello

Division of Surgical Oncology, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Search for more papers by this author
Abhishek Chatterjee

Corresponding Author

Abhishek Chatterjee

Division of Plastic and Reconstructive Surgery, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Division of Surgical Oncology, Department of Surgery, Tufts Medical Center, Boston, Massachusetts, USA

Correspondence: Abhishek Chatterjee ([email protected])

Search for more papers by this author
First published: 16 September 2024

ABSTRACT

Background

Oncoplastic surgery (OPS) has increased in popularity over the recent years. It is a form of breast conservation surgery allowing for larger partial mastectomy (PM) resections followed by either volume displacement or volume replacement reconstruction techniques. However, there is a lack of evidence on the effectiveness and safety of OPS with radiotherapy (OPS + RT) in high-risk breast cancer phenotypes, such as triple negative breast cancer (TNBC) and HER2 positive (HER2+) patients. Our aim was to compare the breast cancer-specific survival (BCSS) and postoperative surgical complications in OPS + RT compared to PM alone with radiation (PM + RT) and total mastectomy (MTX) without radiotherapy (MTX-RT).

Methods

Patient data were analyzed from the Surveillance, Epidemiology, and End Results (SEER) cancer registries from January 1, 2012 to December 31, 2020. Patients were stratified according to the type of surgery. Cox regression analysis was performed to assess prognostic factors of BCSS.

Results

A total of 24 621 patients with high-risk breast cancer phenotypes were identified, 180 underwent OPS + RT; 13 402, PM + RT; and 11 039 MTX-RT. OPS + RT was more frequently performed in younger (mean age of 65.53 years, SD: 9.29, p < 0.001), non-Hispanic White (90.5% vs. 77.7% vs. 76.3%) and single women (17.9% vs. 12.1% vs. 13.3%). MTX-RT was usually performed in patients with high histological grade, TNBC, and higher stages. Overall complication rates were higher in the MTX-RT, compared to OPS + RT and PM + RT, 2%, 1.1%, and 0.7%, respectively, p < 0.001. Rates of hematoma and surgical site infections were higher in the MTX-RT group. With a median follow-up of 46 months, OPS + RT had better BCSS rates at 5 years compared to PM + RT and MTX-RT (97.1% vs. 94.7% vs. 89.8%, p < 0.001). MTX-RT was found to be an independent prognostic factor of worse BCSS compared to OPS + RT (hazard ratio [HR] = 2.584; 95% confidence interval [CI]: 1.005–7.171), while PM + RT had no difference compared to OPS + RT (HR = 1.670, 95% CI: 0.624–4.469).

Conclusions

OPS is a safe breast surgical option in patients with HER2+ and TNBC. Patients with high-risk phenotypes who underwent OPS + RT and have similar BCSS and complication rates compared to standard breast surgical options. As such, OPS should be considered as an option whenever breast conservation surgery is being discussed.

Conflict of Interest

Dr. Chatterjee is a consultant for 3M and Royal, Molnylcke, and Dilon. Other authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available upon request at Surveillance, Epidemiology, and End Results (SEER) after approval by the Committee.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.